The revised International Health Regulations (IHR) enter into force on Friday, 15 June. The Regulations consist of a comprehensive and tested set of rules and procedures which will help to make the world more secure from threats to global health. They were agreed by the World Health Assembly in 2005 and represent a major step forward in international public health security.
Higher immune cell counts in AIDS patients treated with highly active antiretroviral therapy (HAART) are associated a lower incidence of Kaposi sarcoma and non-Hodgkin lymphoma.
New vaccines are available to make significant gains against cervical cancer deaths and debilitating pain from shingles, but infectious diseases experts warn that their full potential will not be realized without changes in the way vaccines for adults and adolescents are promoted, financed and delivered in the United States.
Reported cases of Lyme disease have more than doubled since 1991, when Lyme became a nationally notifiable disease, according to a report by the Centers for Disease Control and Prevention (CDC). The report also said 93 percent of reported cases were concentrated in 10 states.
The U.S. Department of Health and Human Services (HHS) today assembled 100 influential leaders from the employer, faith-based, civic and health care communities to participate in a forum to help Americans become more prepared for an influenza pandemic.
A team led by Horst Kunst at the University of Mainz has found a way to bind a molecule that is typical for tumors to a carrier protein without irritating the immune system. As they report in the journal Angewandte Chemie, their method is based on an immunocompatible connection by way of a sulfur atom, namely, a thioether.
New evidence supports the link between genetic factors and certain adverse events related to smallpox vaccination. The study, published in the July 15 issue of the Journal of Infectious Diseases, now available online, may have implications for predicting adverse events from other live vaccines.
The Meningitis Vaccine Project (MVP) released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine?expected to sell initially for 40 US cents a dose?will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, have discovered a survival mechanism in a common type of bacteria that can cause illness. The mechanism lets the bacteria protect itself by warding off attacks from antimicrobial peptides (AMPs), which are defense molecules sent by the body to kill bacteria.
The Meningitis Vaccine Project today released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine — expected to sell initially for 40 US cents a dose — will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region.